Percutaneous Intra-meniscal platelet-rich plasma injection for meniscal tears: A mid-term.

IF 0.5 4区 医学 Q4 ORTHOPEDICS
Bushu Harna, Shivali Arya, Manish Khanna
{"title":"Percutaneous Intra-meniscal platelet-rich plasma injection for meniscal tears: A mid-term.","authors":"Bushu Harna, Shivali Arya, Manish Khanna","doi":"10.52628/90.4.13408","DOIUrl":null,"url":null,"abstract":"<p><p>Percutaneous intra-meniscal platelet-rich plasma (PRP) is a promising tool for managing low-grade meniscal injuries in non-athletic patients. The study evaluates the clinical and radiological outcomes of PRP intra-meniscal injection in meniscal tears. Forty-eight patients were injected with 3 injections of PRP at an interval of one week with a standardised technique under sonographic guidance. All the patients had MRI evidence of meniscal injury with failed conservative management for at least 3 months. The IKDC score and VAS score were recorded initially and during follow-ups. MRI was performed on at least 12 months post-injection. Medial meniscus tear (n=33) was most commonly present. The mean follow-up of the patient was 14.4 months (Range: 12-16 months) except for 1 patient. Horizontal or oblique tears were the most common injury suffered by the patients (n=35). According to MRI classification, 6 patients had grade 1 lesions, 28 patients had grade 2 lesions, and 14 patients had grade 3 lesions. The mean IKDC and VAS scores improved significantly at the last follow-up. Pain at the site of the injection for 1-2 days was the most common adverse effect. Two patients were surgically intervened at 4 and 6 months respectively. Intra-meniscal PRP injection can be a promising modality to manage low-grade meniscal injuries. It is easy, and minimally invasive to manage meniscal tears. Although there was no radiological evidence of healing, clinical improvement was seen in all the patients. Further, long-term randomized studies are required to ascertain the benefits.</p>","PeriodicalId":7018,"journal":{"name":"Acta orthopaedica Belgica","volume":"90 4","pages":"623-628"},"PeriodicalIF":0.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta orthopaedica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.52628/90.4.13408","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Percutaneous intra-meniscal platelet-rich plasma (PRP) is a promising tool for managing low-grade meniscal injuries in non-athletic patients. The study evaluates the clinical and radiological outcomes of PRP intra-meniscal injection in meniscal tears. Forty-eight patients were injected with 3 injections of PRP at an interval of one week with a standardised technique under sonographic guidance. All the patients had MRI evidence of meniscal injury with failed conservative management for at least 3 months. The IKDC score and VAS score were recorded initially and during follow-ups. MRI was performed on at least 12 months post-injection. Medial meniscus tear (n=33) was most commonly present. The mean follow-up of the patient was 14.4 months (Range: 12-16 months) except for 1 patient. Horizontal or oblique tears were the most common injury suffered by the patients (n=35). According to MRI classification, 6 patients had grade 1 lesions, 28 patients had grade 2 lesions, and 14 patients had grade 3 lesions. The mean IKDC and VAS scores improved significantly at the last follow-up. Pain at the site of the injection for 1-2 days was the most common adverse effect. Two patients were surgically intervened at 4 and 6 months respectively. Intra-meniscal PRP injection can be a promising modality to manage low-grade meniscal injuries. It is easy, and minimally invasive to manage meniscal tears. Although there was no radiological evidence of healing, clinical improvement was seen in all the patients. Further, long-term randomized studies are required to ascertain the benefits.

经皮半月板内富血小板血浆注射治疗半月板撕裂:中期研究。
经皮半月板内富血小板血浆(PRP)是一种很有前途的工具,用于管理低级别半月板损伤的非运动患者。本研究评估半月板撕裂中半月板内注射PRP的临床和放射学结果。48例患者在超声引导下采用标准化技术,每隔一周注射3次PRP。所有患者均有半月板损伤的MRI证据,保守治疗至少3个月失败。在初始和随访期间分别记录IKDC评分和VAS评分。在注射后至少12个月进行MRI检查。内侧半月板撕裂(n=33)最为常见。除1例患者外,平均随访14.4个月(范围12-16个月)。水平或斜向撕裂是患者最常见的损伤(n=35)。根据MRI分级,1级病变6例,2级病变28例,3级病变14例。在最后一次随访时,平均IKDC和VAS评分显著改善。注射部位疼痛1-2天是最常见的不良反应。2例患者分别在4个月和6个月时进行手术干预。半月板内PRP注射可能是一种有前途的方式来管理低级别半月板损伤。治疗半月板撕裂很容易,而且微创。虽然没有放射学证据表明愈合,但所有患者的临床改善都可见。此外,需要长期随机研究来确定其益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta orthopaedica Belgica
Acta orthopaedica Belgica 医学-整形外科
CiteScore
0.70
自引率
0.00%
发文量
58
审稿时长
4-8 weeks
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信